Last reviewed · How we verify
NCT04770701
Extracts of Plants Eclipta Prostrata, Dioscorea Cirrhosa, Phyllanthus Urinaria, Adenosma Glutinosum, Impatiens Balsamina and Ascorbic Acid Use for in Protecting and Increasing CD4+ T Lymphocytes; B Lymphocytes Level in HIV/AIDS Patients.
Phase 4 trial testing Ahah Drug in HIV-1-infection. Withdrawn.
7 June 2025
Quick facts
| Lead sponsor | Trieu, Nguyen Thi, M.D. |
|---|---|
| Phase | Phase 4 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 20 September 2020 |
| Primary completion | 7 June 2025 |
| Estimated completion | 6 June 2026 |
| Sites | 1 location across Vietnam |
Drugs / interventions tested
- Ahah Drug — full drug profile →
- Ahah Placebo
Conditions studied
- HIV-1-infection — all drugs for HIV-1-infection →
- AIDS — all drugs for AIDS →
Sponsor
Trieu, Nguyen Thi, M.D. — full company profile →
Who can join
Adults 18 to 60, any sex, with HIV-1-infection or AIDS. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
The CD4 cell count measurement
Time frame: - 9 months
HIV is a fatal infection, characterized by the targeting and destruction of CD4 T lymphocytes in the peripheral blood.
Sponsor's own description
This is a plant-based medication used to increase the amount, protect, and reduce HIV's impact on T and B lymphocytes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04770701
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HIV-1-infection
Currently open trials in the same condition.
- NCT07293559 — Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States · recruiting
- NCT06919016 — A Study to Evaluate the Safety and Immunogenicity of the V3-region Directed Immunogens DV700P-RNA Followed by DV701B1.1- · Phase 1 · active not recruiting
- NCT06554717 — Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV · Phase 2 · recruiting
- NCT06774872 — Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Succes · Phase 2 · recruiting
- NCT06890988 — Ending the Epidemic Interventions in the Dental Setting - UH3 · NA · recruiting
Other Trieu, Nguyen Thi, M.D. trials
Trials by the same sponsor.
- NCT05399212 — Composition for Treating Spermatogenesis and Semen Disorders / FPT-20 · Phase 4 · completed
- NCT04762316 — Composition for Treating Uterine Fibroid (SB-UF) · Phase 4 · completed
- NCT07084948 — Using Flavonoids to Kill Hepatitis B Virus · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04770701 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Trieu, Nguyen Thi, M.D.
- Last refreshed: 1 June 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04770701.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing